0.29
-0.0305(-9.59%)
Currency In USD
| Previous Close | 0.32 |
| Open | 0.32 |
| Day High | 0.33 |
| Day Low | 0.29 |
| 52-Week High | 1.53 |
| 52-Week Low | 0.18 |
| Volume | 1.33M |
| Average Volume | 1.02M |
| Market Cap | 29.06M |
| PE | -0.24 |
| EPS | -1.2 |
| Moving Average 50 Days | 0.31 |
| Moving Average 200 Days | 0.39 |
| Change | -0.03 |
If you invested $1000 in FibroGen, Inc. (FGEN) 10 years ago, it would be worth $16.43 as of June 01, 2025 at a share price of $0.288. Whereas If you bought $1000 worth of FibroGen, Inc. (FGEN) shares 5 years ago, it would be worth $8.55 as of June 01, 2025 at a share price of $0.288.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroGen to Report First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 05, 2025 8:05 PM GMT
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Apr 02, 2025 8:05 PM GMT
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen’s management team will
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
GlobeNewswire Inc.
Mar 28, 2025 11:00 AM GMT
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025 SAN F